

IFW

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 27, 2004
Date

Lawrence Teague
Lawrence Teague

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ronald Berenson et al.
Application No. : 10/729,822
Filed : December 5, 2003
For : COMPOSITIONS AND METHODS FOR ELIMINATING
UNDESIRE SUBPOPULATIONS OF T CELLS IN PATIENTS
WITH IMMUNOLOGICAL DEFECTS RELATED TO
AUTOIMMUNITY AND ORGAN OR HEMATOPOIETIC STEM
CELL TRANSPLANTATION

Art Unit : 1632
Docket No. : 980034.422C1
Date : October 27, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior U.S. Patent Application No. 10/603,577, filed June 24, 2003. The references listed on the attached Form PTO-1449 were submitted to and/or cited by the Patent and


Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461


JAU:ljt

Enclosures:

Postcard
Transmittal Form
Form PTO-1449 (26 Sheets)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\500738



TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/729,822
Filing Date	December 5, 2003
First Named Inventor	Ronald Berenson
Art Unit	1632
Examiner Name	
Attorney Docket No.	980034.422C1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Form PTO-1449 (26 Sheets) <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (<i>please identify below</i>): _____ _____ _____
---	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Julie A. Urvater, Ph.D., Patent Agent Reg No. 50,461	Customer Number 00500
Signature		
Date	October 27, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Lawrence Teague	
Signature		Date: October 27, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1522478

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.422C1APPLICATION NO.
10/729,822**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

NOV 01 2004

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,081,029	01/14/92	Zarling et al.	435	172.3	
	AB	5,106,746	04/21/92	Ho	435	240.25	
	AC	5,190,878	03/02/93	Wilhelm	435	285	
	AD	5,223,426	06/29/93	Skibbens et al.	435	240.27	
	AE	5,443,983	08/22/95	Ochoa et al.	435	240.2	
	AF	5,468,635	11/21/95	Komiya et al.	435	240.21	
	AG	5,470,730	11/28/95	Greenberg et al.	435	172.3	
	AH	5,635,354	06/03/97	Kourilsky et al.	435	6	
	AI	5,674,704	10/07/97	Goodwin et al.	435	69.1	
	AJ	5,677,139	10/14/97	Johnson et al.	435	29	
	AK	5,688,915	11/18/97	Ron et al.	530	380	
	AL	5,728,388	03/17/98	Terman	424	237.1	
	AM	5,735,279	04/07/98	Klaveness et al.	128	654	
	AN	5,738,852	04/14/98	Robinson et al.	424	199.1	
	AO	5,759,546	06/02/98	Weinberg et al.	424	179.1	
	AP	5,766,947	06/16/98	Rittershaus et al.	435	334	
	AQ	5,776,966	07/07/98	North	514	410	
	AR	5,804,442	09/08/98	Romet-Lemonne et al.	435	374	
	AS	5,824,551	10/20/98	Damme et al.	435	375	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AT					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AU	
--	----	--

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	5,827,642	10/27/98	Riddell et al.	435	2	
	BB	5,830,462	11/03/98	Crabtree et al.	424	93.21	
	BC	5,830,473	11/03/98	Thierfelder	424	172.1	
	BD	5,837,477	11/17/98	Germain et al.	435	7.24	
	BE	5,843,435	12/01/98	Slavin	424	93.71	
	BF	5,843,635	12/01/98	Schlossman et al.	435	5	
	BG	5,869,270	02/09/99	Rhode et al.	435	7.24	
	BH	5,869,337	02/09/99	Crabtree et al.	435	372.3	
	BI	5,871,753	02/16/99	Crabtree et al.	424	280.1	
	BJ	5,872,222	02/16/99	Chang	530	391.1	
	BK	5,888,807	03/30/99	Palsson et al.	435	293.2	
	BL	5,910,403	06/08/99	Hellerstein	435	4	
	BM	5,928,639	07/27/99	Slavin	424	93.71	
	BN	5,935,575	08/10/99	Lenardo et al.	424	184.1	
	BO	5,942,607	08/24/99	Freeman et al.	536	23.5	
	BP	5,962,319	10/05/99	Ogawa et al.	435	325	
	BQ	5,962,320	10/05/99	Robinson	435	366	
	BR	5,976,533	11/02/99	Skibbens et al.	424	144.1	
	BS	5,980,892	11/09/99	Skibbens et al.	424	144.1	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	BT						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	BU						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
CA	5,985,653	11/16/99	Armstrong et al.	435	303.1		
CB	5,989,546	11/23/99	Lenardo	424	184.1		
CC	6,010,902	01/04/00	Ledbetter et al.	435	328		
CD	6,011,018	01/04/00	Crabtree et al.	514	31		
CE	6,040,177	03/21/00	Riddell et al.	435	372.3		
CF	6,043,082	03/28/00	Crabtree et al.	435	320.1		
CG	6,046,047	04/04/00	Crabtree et al.	435	320.1		
CH	6,048,526	04/11/00	Skibbens et al.	424	144.1		
CI	6,063,625	05/16/00	Crabtree et al.	435	375		
CJ	6,083,503	07/04/00	Lenardo	424	184.1		
CK	6,096,532	08/01/00	Armstrong et al.	435	286.5		
CL	6,113,901	09/05/00	Bluestone	424	154.1		
CM	6,117,982	09/12/00	Chang	530	391.1		
CN	6,126,945	10/03/00	Terman et al.	424	237.1		
CO	6,129,916	10/10/00	Chang	424	179.1		
CP	6,140,120	10/31/00	Crabtree et al.	435	372.3		
CQ	6,143,291	11/07/00	June et al.	424	93.21		
CR	6,143,292	11/07/00	Slavin	424	93.7		
CS	6,143,297	11/07/00	Bluestone	424	184.1		

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
CT					

OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
CU		

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
DA	6,165,787	12/26/00	Crabtree et al.	435	372.3		
DB	6,171,799	01/09/01	Skibbens et al.	435	7.1		
DC	6,180,097	01/30/01	Terman	424	93.1		
DD	6,197,298	03/06/01	Chang	424	179.1		
DE	6,210,669	04/03/01	Aruffo et al.	424	144.1		
DF	6,221,351	04/24/01	Terman	424	93.71		
DG	6,232,445	05/15/01	Rhode et al.	530	387.3		
DH	6,251,385	06/26/01	Terman	424	93.7		
DI	6,258,357	07/10/01	Spaner	424	93.71		
DJ	6,284,879	09/04/01	Faustman	536	23.1		
DK	6,290,955	09/18/01	Thierfelder	424	130.1		
DL	6,309,645	10/30/01	Rhode et al.	424	192.1		
DM	6,316,257	11/13/01	Flyer et al.	435	372.3		
DN	6,338,845	01/15/02	Terman	424	93.1		
DO	6,340,461	01/22/02	Terman	424	193.1		
DP	6,355,779	03/12/02	Goodwin et al.	530	388.23		
DQ	6,399,054	06/04/02	Casorati et al.	424	93.21		
DR	6,406,699	06/18/02	Wood	424	184.1		

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
DS					

OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
DT		

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA	6,461,806	10/08/02	Hellerstein	435	4	
	EB	6,465,251	10/15/02	Schultze et al.	435	377	
	EC	6,488,933	12/03/02	Cohen et al.	424	185.1	
	ED	6,566,082	05/20/03	Weinberg et al.	435	7.24	
	EE	6,576,428	06/10/03	Assenmacher et al.	435	7.1	
	EF	6,576,466	06/10/03	Jungfer et al.	435	372.3	
	EG	6,602,709	08/05/03	Albert et al.	435	372	
	EH	6,610,542	08/26/03	Bell et al.	435	377	
	EI	6,656,471	12/02/03	Sastry et al.	424	188.1	
	EJ	6,689,605	02/10/04	Mountz et al.	435	320.1	
	EK	6,692,746	02/17/04	Terman et al.	424	184.1	
	EL	6,719,972	04/13/04	Gribben et al.	424	154.1	
	EM	2001/0028879	10/11/01	Spaner	424	93.7	
	EN	2001/0051151	12/13/01	Lamb, Jr.	424	93.7	
	EO	2001/0031253	10/18/01	Gruenberg	424	93.1	
	EP	2002/0004041	01/10/02	Albert et al.	424	93.21	
	EQ	2002/0006409	01/17/02	Wood	424	184.1	
	ER	2002/0009448	01/24/02	Weiner et al.	424	154.1	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	ES						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	ET						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA	2002/0034513	03/21/02	Rhode et al.	424	184.1	
	FB	2002/0034517	03/21/02	Brasel et al.	424	192.1	
	FC	2002/0037860	03/28/02	D'Andrea et al.	514	19	
	FD	2002/0039569	04/04/02	Jungfer et al.	424	85.2	
	FE	2002/0090362	07/11/02	Stauss	424	93.21	
	FF	2002/0091079	07/11/02	Rhode et al.	514	12	
	FG	2002/0119571	08/29/02	Ritter et al.	435	456	
	FH	2002/0146396	10/10/02	Albert et al.	424	93.21	
	FI	2002/0164331	11/07/02	Exley et al.	424	144.1	
	FJ	2002/0176850	11/28/02	Slavin	424	93.21	
	FK	2002/0177554	11/28/02	Verheijden et al.	514	12	
	FL	2002/0182730	12/05/02	Gruenberg	435	375	
	FM	2002/0197716	12/26/02	Flyer et al.	435	372	
	FN	2003/0039650	02/27/03	Gruenberg	424	144.1	
	FO	2003/0113328	06/19/03	Roifman et al.	424	146.1	
	FP	2003/0113341	06/19/03	Lynch et al.	424	185.1	
	FQ	2003/0118659	06/26/03	August et al.	424	491	
	FR	2003/0134341	07/17/03	Gruenberg	435	7.21	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	FS						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	FT						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.		
				FILING DATE December 5, 2003		GROUP ART UNIT 1632

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
GA	2003/0134415	07/17/03	Gruenberg	435	372		
GB	2003/0165531	09/04/03	Lynch et al.	424	192.1		
GC	2003/0170238	09/11/03	Gruenberg	424	144.1		
GD	2003/0175242	09/18/03	Gruenberg	424	93.2		
GE	2003/0175272	09/18/03	Gruenberg	424	144.1		
GF	2003/0176378	09/18/03	Weiner et al.	514	44		
GG	2003/0190323	10/09/03	Cohen et al.	424	185.1		
GH	2003/0194395	10/16/03	Gruenberg et al.	424	93.7		
GI	2003/0219463	11/27/03	Falkenburg et al.	424	277.1		
GJ	2004/0023377	02/05/04	Assenmacher et al.	435	372		
GK	2004/0037845	02/26/04	Brasel et al.	424	185.1		
GL	2004/0072749	04/15/04	Zochoer et al.	514	12		
GM	2004/0156860	08/12/04	Weiner et al.	424	185.1		
GN	2004/0157792	08/12/04	Mountz et al.	514	44		
GO	2004/0161433	08/19/04	Teshigawara et al.	424	277.1		
GP	2004/0180050	09/16/04	Hoffman	424	144.1		
GQ	2004/0180808	09/16/04	Nye et al.	514	2		
GR	2004/0185048	09/23/04	Strom et al.	424	145.1		

FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
			YES	NO	
GS					

OTHER ART <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>			
GT			

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	HB	CA 2304268 A1	04/01/99	Canada			
	HC	EP 242216 A1	10/21/87	EPO			
	HD	EP 340109 B1	05/28/97	EPO			
	HE	EP 440373 B1	04/23/97	EPO			
	HF	EP 633930 B1	04/26/00	EPO			
	HG	WO 86/04334	07/31/86	WIPO			
	HH	WO 91/18629	12/12/91	WIPO			
	HI	WO 92/09628	06/11/92	WIPO			
	HJ	WO 93/14789	08/05/93	WIPO			
	HK	WO 93/24127	12/09/93	WIPO			
	HL	WO 93/24136	12/09/93	WIPO			
	HM	WO 94/02156	02/03/94	WIPO			
	HN	WO 94/03202	02/17/94	WIPO			
	HO	WO 94/12196	06/09/94	WIPO			
	HP	WO 94/18317	08/18/94	WIPO			
	HQ	WO 94/19009	09/01/94	WIPO			
	HR	WO 94/23734	10/27/94	WIPO			
	HS	WO 94/28926	12/22/94	WIPO			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	HT						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
IA							

FOREIGN PATENT DOCUMENTS						
DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
			YES	NO		
IB	WO 95/09652	04/13/95	WIPO			
IC	WO 95/21251	08/10/95	WIPO			
ID	WO 95/24910	09/21/95	WIPO			
IE	WO 95/32735	12/07/95	WIPO			
IF	WO 95/33770	12/14/95	WIPO			
IG	WO 96/06929	03/07/96	WIPO			
IH	WO 96/15153	05/23/96	WIPO			
II	WO 96/33265	10/24/96	WIPO			
IJ	WO 96/34622	11/07/96	WIPO			
IK	WO 96/37208	11/28/96	WIPO			
IL	WO 96/38158	12/05/96	WIPO			
IM	WO 97/00270	01/03/97	WIPO			
IN	WO 97/01304	01/16/97	WIPO			
IO	WO 97/02016	01/23/97	WIPO			
IP	WO 97/05233	02/13/97	WIPO			
IQ	WO 97/05239	02/13/97	WIPO			
IR	WO 97/10361	03/20/97	WIPO			

OTHER ART <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>			
IS			

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.422C1APPLICATION NO.
10/729,822**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)APPLICANTS
Ronald Berenson et al.FILING DATE
December 5, 2003GROUP ART UNIT
1632**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	JB	WO 97/12633	04/10/97	WIPO		
	JC	WO 97/32970	09/12/97	WIPO		
	JD	WO 97/37004	10/09/97	WIPO		
	JE	WO 97/39722	10/30/97	WIPO		
	JF	WO 97/44667	11/27/97	WIPO		
	JG	WO 98/21314	05/22/98	WIPO		
	JH	WO 98/51820	11/19/98	WIPO		
	JI	WO 98/52615	11/26/98	WIPO		
	JJ	WO 98/56819	12/17/98	WIPO		
	JK	WO 98/56823	12/17/98	WIPO		
	JL	WO 99/13904	03/25/99	WIPO		
	JM	WO 99/21572	05/06/99	WIPO		
	JN	WO 99/38953	08/05/99	WIPO		
	JO	WO 99/51247	10/14/99	WIPO		
	JP	WO 99/52928	10/21/99	WIPO		
	JQ	WO 99/55843	11/04/99	WIPO		
	JR	WO 99/58977	11/18/99	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	JS	
--	----	--

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.422C1APPLICATION NO.
10/729,822**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	KB	WO 00/02520	01/20/00	WIPO		X
	KC	WO 00/02520	01/20/00	WIPO	X	
	KD	WO 00/15767	03/23/00	WIPO		
	KE	WO 00/22124	04/20/00	WIPO		
	KF	WO 00/29008	05/25/00	WIPO		
	KG	WO 00/31138	06/02/00	WIPO		
	KH	WO 00/44893	08/03/00	WIPO		
	KI	WO 00/51432	09/08/00	WIPO		
	KJ	WO 00/52046	09/08/00	WIPO		
	KK	WO 00/56356	09/28/00	WIPO		
	KL	WO 00/59538	10/12/00	WIPO		
	KM	WO 00/66764	11/09/00	WIPO		
	KN	WO 01/22970	04/05/01	WIPO		
	KO	WO 01/24771	04/12/01	WIPO		
	KP	WO 01/29192	04/26/01	WIPO		
	KQ	WO 01/43695	06/21/01	WIPO		
	KR	WO 01/49743	07/12/01	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	KS	
--	----	--

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.422C1APPLICATION NO.
10/729,822**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	LB	WO 01/52664	07/02601	WIPO		
	LC	WO 01/87333	11/22/01	WIPO		
	LD	WO 01/88116	11/22/01	WIPO		
	LE	WO 01/98357	12/27/01	WIPO		
	LF	WO 02/09674	02/07/02	WIPO		
	LG	WO 02/16414	02/28/02	WIPO		
	LH	WO 02/22790	03/21/02	WIPO		
	LI	WO 02/22805	03/21/02	WIPO		
	LJ	WO 02/28385	04/11/02	WIPO		
	LK	WO 03/024312	03/27/03	WIPO		
	LL	WO 03/025158	03/27/03	WIPO		
	LM	WO 03/034820	05/01/03	WIPO		
	LN	WO 03/043643	05/30/03	WIPO		
	LO	WO 03/077658	09/25/03	WIPO		
	LP					
	LQ					
	LR					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	LS	
--	----	--

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.422C1

APPLICATION NO.

10/729,822

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	MB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	MC	Allegretta, M. et al., "Homologies between T Cell Receptor Junctional Sequences Unique to Multiple Sclerosis and T Cells Mediating Experimental Allergic Encephalomyelitis," <i>The Journal of Clinical Investigation</i> 94: 105-109, July 1994.
	MD	Anderton, S.M. et al., "Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells," <i>Eur. J. Immunol.</i> 29(6): 1850-1857, June 1999.
	ME	Arenz, M. et al., "Antigen-independent in vitro expansion of T cells does not affect the T cell receptor V β repertoire," <i>J. Mol. Med.</i> 75: 678-686, 1997.
	MF	Azuma, T. et al., "Induction of apoptosis of activated murine splenic T cells by cycloprodigiosin hydrochloride, a novel immunosuppressant," <i>Immunopharmacology</i> 46(1): 29-37, January 2000.
	MG	Baroja, M.L. et al., "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> 120: 205-217, 1989.
	MH	Bender, A. et al., "T Cell Receptor Repertoire in Polymyositis: Clonal Expansion of Autoaggressive CD8 ⁺ T Cells," <i>J. Exp. Med.</i> 181: 1863-1868, May 1995.
	MI	Bergstr�sser, P.R. et al., "T Cell-Mediated Terminal Maturation of Dendritic Cells," in <i>Dendritic Cells in Fundamental and Clinical Immunology</i> , Ricciardi-Castagnoli (Ed.), Plenum Press, New York, 1997, pgs. 65-69.
	MJ	Bishop, C.D.V.A. et al., "Assessing Apoptosis of Developing T Cells by Flow Cytometry" in <i>Methods in Molecular Biology</i> , vol. 134: <i>T Cell Protocols: Development And Activation</i> , Kears, K.P. ed., Humana Press, 1999, pgs. 117-131.
	MK	Boehncke, W-H. et al., "T-Cell-Receptor Repertoire in Chronic Plaque-Stage Psoriasis Is Restricted and Lacks Enrichment of Superantigen-Associated V β Regions," <i>J. Invest. Dermatol.</i> 104: 725-728, 1995.
	ML	Bonyhadi, M. et al., "Xcellerate: An Autologous T Cell Immunotherapy Approach for Treating B-Cell Lymphocytic Leukemia (B-CLL)," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 1, ABSTRACT # 3616.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.422C1

APPLICATION NO.

10/729,822

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
			YES	NO
NB				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

NC	Borthwick, N.J. et al., "Loss of CD28 expression on CD8 ⁺ T cells is induced by IL-2 receptor γ chain signaling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis," <i>International Immunology</i> 12(7): 1005-1013, 2000.
ND	Bour, H. et al., "T-Cell Repertoire Analysis in Chronic Plaque Psoriasis Suggests an Antigen-Specific Immune Response," <i>Human Immunology</i> 60: 665-676, 1999.
NE	Broomé, U. et al., "Preferential V β 3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis," <i>Journal of Hepatology</i> 26: 527-534, 1997.
NF	Bruserud and Pawelec, "Cyclosporine A and FK506 Show Similar Immunosuppressive Effects on Long-term <i>in Vitro</i> T-Cell Proliferation," <i>Int. J. Immunopharmac.</i> 15(2): 93-97, 1993.
NG	Bulfone-Paus, S. et al., "An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression," <i>Transplantation</i> 69(7): 1386-1391, April 2000.
NH	Carlens, S. et al., "Ex vivo T lymphocyte expansion for retroviral transduction: Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution," <i>Experimental Hematology</i> 28: 1137-1146, 2000.
NI	Carpenter, P.A. et al., "Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells," <i>J. Immunol.</i> 165(11): 6205-6213, December 2000.
NJ	Carpenter, P.A. et al., "Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive <i>in vivo</i> ," <i>Transplant Proc.</i> 32(7): 1545-1546, November 2000.
NK	Carroll, H.P. et al., "Accelerating the induction of Fas-mediated T cell apoptosis: a strategy for transplant tolerance?," <i>Clin. Exp. Immunol.</i> 126(3): 589-597, December 2001.
NL	Christen, U. et al., "Apoptosis of Autoreactive CD8 Lymphocytes as a Potential Mechanism for the Abrogation of Type 1 Diabetes by Islet-Specific TNF- α Expression at a Time When the Autoimmune Process Is Already Ongoing," <i>Ann. N.Y. Acad. Sci.</i> 958: 166-169, 2002.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	OA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	OB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	OC	Cioca, D.P. et al., "Apoptosis of peripheral blood lymphocytes is induced by catecholamines," <i>Jpn. Heart J.</i> 41(3): 385-398, May 2000.					
	OD	Claret, E.J. et al., "Characterization of T Cell Repertoire in Patients with Graft-Versus-Leukemia After Donor Lymphocyte Infusion," <i>Journal of Clinical Investigation</i> 100(4): 855-866, August 1997.					
	OE	Cohen, P.A. et al., "T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance," <i>Critical Reviews in Immunology</i> 21: 215-248, 2001.					
	OF	Combadière, B. et al., "Selective Induction of Apoptosis in Mature T Lymphocytes by Variant T Cell Receptor Ligands," <i>Journal of Experimental Medicine</i> 187(3): 349-355, February 2, 1998.					
	OG	Creson, J. et al., "The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro," <i>Journal Of Virology</i> , 73(11):9337-9347, November 1999.					
	OH	Dao, T. et al., "Natural Human Interferon- α Augments Apoptosis in Activated T Cell Line," <i>Cellular Immunology</i> 155: 304-311, 1994.					
	OI	Davey, M.P. et al., "TCRB Clonotypes Are Present in CD4 ⁺ T Cell Populations Prepared Directly from Rheumatoid Synovium," <i>Human Immunology</i> 55: 11-21, 1997.					
	OJ	Davies, T.F., "A new role for methimazole in autoimmune thyroid disease: inducing T cell apoptosis," <i>Thyroid</i> 10(7): 525-526, July 2000.					
	OK	Di Renzo, M. et al., "Enhanced apoptosis of T cells in common variable immunodeficiency (CVID): role of defective CD28 co-stimulation," <i>Clin. Exp. Immunol.</i> 120: 503-511, 2000.					
	OL	Di Sabatino, A. et al., "Apoptosis and peripheral blood lymphocyte depletion in coeliac disease," <i>Immunology</i> 103: 435-440, 2001.					
	OM	Dietrich, P-Y et al., "TCR analysis reveals significant repertoire selection during <i>in vitro</i> lymphocyte culture," <i>International Immunology</i> 9(8): 1073-1083, 1997.					
	ON	Ebata, T. et al., "Rapid induction of CD95 ligand and CD4 ⁺ T cell-mediated apoptosis by CD137 (4-1BB) costimulation," <i>Eur. J. Immunol.</i> 31(5): 1410-1416, May 2001.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	PA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	PB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	PC	Ebert, O. et al., "Lymphocyte apoptosis: induction by gene transfer techniques," <i>Gene Therapy</i> 4: 296-302, 1997.					
	PD	Epperson, D.E. et al., "Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process," <i>Leukemia Research</i> 25: 1075-1083, 2001.					
	PE	Fishman-Lobell, J. et al., "CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using Attractors," <i>J. Immunol. Methods</i> 257(1-2): 71-82, November 2001.					
	PF	Friedman, T.M. et al., "Repertoire Analysis of CD8 ⁺ T Cell Responses to Minor Histocompatibility Antigens Involved in Graft-Versus-Host Disease," <i>The Journal of Immunology</i> 161: 41-48, 1998.					
	PG	Fukumoto, H. et al., "Activation-induced apoptosis of peripheral lymphocytes treated with 7-hydroxystaurosporine, UCN-01," <i>Investigational New Drugs</i> 17: 335-341, 1999					
	PH	Fuss, I.J. et al., "Anti-Interleukin 12 Treatment Regulates Apoptosis of Th1 T Cells in Experimental Colitis in Mice," <i>Gastroenterology</i> 117: 1078-1088, 1999.					
	PI	Fyhr, I-M et al., "T cell receptor β -chain repertoire in inclusion body myositis," <i>Journal of Neuroimmunology</i> 91: 129-134, 1998.					
	PJ	Goronzy and Weyand, "Thymic function and peripheral T-cell homeostasis in rheumatoid arthritis," <i>Trends in Immunology</i> 22(5): 251-255, May 2001.					
	PK	Goronzy, J.J. et al., "T Cell Receptor Repertoire in Rheumatoid Arthritis," <i>Intern. Rev. Immunol.</i> 17: 339-363, 1998.					
	PL	Greer, J.P. et al., "T Cell and NK Cell Lymphoproliferative Disorders," <i>Hematology</i> 2001: 259-281.					
	PM	Groh, V. et al., "Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis," <i>Proceedings of the National Academy of Sciences</i> 100(16): 9452-9457, August 5, 2003.					
	PN	Haegert, D.G. et al., "Does a shift in the T-cell receptor repertoire precede the onset of MS," <i>Neurology</i> 53: 485-490, 1999.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	QA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	QB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	QC	Hall, F.C. et al., "TCR β spectratyping in RA: evidence of clonal expansions in peripheral blood lymphocytes," <i>Ann. Rheum. Dis.</i> 57: 319-322, 1998.					
	QD	Hami, L. et al., "Xcellerate™: A Platform Process for the GMP Manufacture of Activated T Cells for the Treatment of Patients with Cancer and Immune Dysfunction," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 1, abstract # 3630.					
	QE	Hashimoto, Y. et al., "Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis," <i>Clinical Exp. Immunol.</i> 125(1): 19-24, July 2001.					
	QF	Hayashi and Faustman, "Implications of altered apoptosis in diabetes mellitus and autoimmune disease," <i>Apoptosis</i> 6(1/2): 31-45, 2001.					
	QG	Hildeman, D.A. et al., "Reactive Oxygen Species Regulate Activation-Induced T Cell Apoptosis," <i>Immunity</i> 10: 735-744, June 1999.					
	QH	Holbrook, M.R. et al., "Restrictions of T cell receptor β chain repertoire in the peripheral blood of patients with systemic lupus erythematosus," <i>Ann. Rheum. Dis.</i> 55: 627-631, 1996.					
	QI	Holtzman, M.J. et al., "Regulation of T cell apoptosis," <i>Apoptosis</i> 5(5): 459-471, 2000.					
	QJ	Husebekk, A. et al., "Selection and expansion of T cells from untreated patients with CLL: source of cells for immune reconstitution," <i>Cytotherapy</i> 2(3): 187-193, 2000.					
	QK	Iezzi et al., "The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells," <i>Immunity</i> 8: 89-95, January 1998.					
	QL	Inada, H. et al., "T Cell Repertoire in the Liver of Patients with Primary Biliary Cirrhosis," <i>Human Immunology</i> 61: 675-683, 2000.					
	QM	Ino, K. et al., "Activation-induced T cell apoptosis by monocytes from stem cell products," <i>International Immunopharmacology</i> 1: 1307-1319, 2001.					
	QN	Jason & Inge, "The Effects of Mitogens, IL-2 and Anti-CD3 Antibody on the T-Cell Receptor V β Repertoire," <i>Scand. J. Immunol</i> 43: 652-661, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.422C1

APPLICATION NO.

10/729,822

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	RA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	RB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	RC	Kalamasz, D. et al., "Storage Shipment of Freshly Harvested or Cryopreserved Xcellerate™ Activated T Cells for Clinical Applications," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 2, abstract # 5113.
	RD	Kallan, A.A. et al., "Th1-like Cytokine Production Profile and Individual Specific Alterations in TCRBV-gene Usage of T Cells from Newly Diagnosed Type 1 Diabetes Patients after Stimulation with β -cell Antigens," <i>Journal of Autoimmunity</i> 10(6): 589-598, 1997.
	RE	Kang, J-A. et al., "Clonal Expansion of Infiltrating T Cells in the Spinal Cords of SJL/J Mice Infected with Theiler's Virus," <i>The Journal of Immunology</i> 165: 583-590, 2000.
	RF	Karadimitris, A. et al., "Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria," <i>Blood</i> 96(7): 2613-2620, October 1, 2000.
	RG	Kato et al., "Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> 101(5): 1133-1141, March 1998.
	RH	Kay, N.E. et al., "Interleukin 4 content in chronic lymphocytic leukemia (CLL) B cells and blood CD8 ⁺ T cells from B-CLL patients: impact on clonal B-cell apoptosis," <i>British Journal of Haematology</i> 112: 760-767, 2001.
	RI	Kim, G. et al., "CDR3 Size Spectratyping and Sequencing of Spectratype-Derived TCR of Spinal Cord T Cells in Autoimmune Encephalomyelitis," <i>The Journal of Immunology</i> 160: 509-513, 1998.
	RJ	Kirsch, A.H. et al., "Apoptosis of human T-cells: induction by glucocorticoids or surface receptor ligation in vitro and ex vivo," <i>J. Biol. Regul. Homeost. Agents</i> 13(2): 80-89, 1999.
	RK	Koetz, K. et al., "T cell homeostasis in patients with rheumatoid arthritis," <i>Proc. Natl. Acad. Sci.</i> 97(16): 9203-9208, August 1, 2000.
	RL	Kolowos, W. et al., "Detection of restricted junctional diversity of peripheral T cells in SLE patients by spectratyping," <i>Lupus</i> 6: 701-707, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	SA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	SB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	SC	Kornacker, M. et al., "Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells," <i>Immunology Letters</i> 76: 169-173, 2001.					
	SD	Krawczyk, C. et al., "Cbl-b Is a Negative Regulator of Receptor Clustering and Raft Aggregation in T Cells," <i>Immunity</i> 13: 463-473, October 2000.					
	SE	Lamy and Loughran, "Large Granular Lymphocyte Leukemia," <i>Cancer Control</i> 5(1): 25-33, 1998. Available at www.moffitt.usf.edu .					
	SF	Lanzavecchia, A. et al., "In vitro selective expansion of allergen specific T cells from atopic patients," <i>Clinical Exp. Immunol.</i> 52(1): 21-28, April 1983.					
	SG	Lanzavecchia, A., "The Role of Dendritic Cells in the Generation of Effector and Memory T Cell Responses," from <i>The Midwinter Conference of Immunologists</i> , January 22-25, 2000, available at www.midwconferimmunol.org/Midwinter00/sessions/lanzavecchia.html .					
	SH	Larsson, S. et al., "Productive Cytomegalovirus (CMV) Infection Exclusively in CD13-Positive Peripheral Blood Mononuclear Cells from CMV-Infected Individuals," <i>Transplantation</i> , 65(3):411-415, February 15, 1998.					
	SI	Laytragoon-Lewin, N. et al., "Alteration of Cellular Mediated Cytotoxicity, T Cell Receptor Zeta (TcR ζ) and Apoptosis Related Gene Expression in Nasopharyngeal Carcinoma (NPC) Patients: Possible Clinical Relevance," <i>Anticancer Research</i> 20: 1093-1100, 2000.					
	SJ	Lehmann, P.V. et al., "Determinant spreading and the dynamics of the autoimmune T-cell repertoire," <i>Immunology Today</i> 14(5): 203-208, 1993.					
	SK	Levine, B.L. et al., "Antiviral Effect and Ex Vivo CD4 ⁺ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation," <i>Science</i> 272: 1939-1943, June 28, 1996.					
	SL	Levings, M.K. et al., "Human CD25 ⁺ CD4 ⁺ T regulatory cells suppress naïve and memory T cell proliferation and can be expanded in vitro without loss of function," <i>J. Exp. Med.</i> 193(11): 1295-1302, June 2001.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.422C1

APPLICATION NO.

10/729,822

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Ronald Berenson et al.

FILING DATE

December 5, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	TA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	TB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	TC	Li, Q. et al., "Expanded Tumor-reactive CD4 ⁺ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation," <i>Clinical Cancer Research</i> 5: 461-469, February 1999.
	TD	Li, Q. et al., "Immunological Effects of BCG as an Adjuvant in Autologous Tumor Vaccines," <i>Clinical Immunology</i> 94(1): 64-72, January 2000.
	TE	Li, Y. et al., "CDR3 Sequence Motifs Shared by Oligoclonal Rheumatoid Arthritis Synovial T Cells. Evidence for an Antigen-driven Response," <i>Journal of Clinical Investigation</i> 94: 2525-2531, December 1994.
	TF	Liebowitz, D. et al., "Costimulatory approaches to adoptive immunotherapy," <i>Current Opinion in Oncology</i> 10: 533-541, 1998.
	TG	Lim, A. et al., "Spread of Clonal T-Cell Expansions in Rheumatoid Arthritis Patients," <i>Human Immunology</i> 48: 77-83, 1996.
	TH	Lin and Welsh, "Stability and Diveristy of T Cell Receptor Repertoire Usage during Lymphocytic Choriomeningitis Virus Infection of Mice," <i>Journal of Experimental Medicine</i> 188(11): 1993-2005, December 7, 1998.
	TI	Liuzzo, G. et al., "Monoclonal T-Cell Proliferation and Plaque Instability in Acute Coronary Syndromes," <i>Circulation</i> 102: 2883-2888, 2000.
	TJ	Lopez, R.D. et al., "CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56 ⁺ T cells," <i>Cancer Immunol. Immunother.</i> 49: 629-640, 2001.
	TK	Mantegazza, R. et al., "Analysis of T Cell Receptor Repertoire of Muscle-infiltrating T Lymphocytes in Polymyositis. Restricted Va/β Rearrangements May Indicate Antigen-driven Selection," <i>Journal of Clinical Investigation</i> 91: 2880-2886, June 1993.
	TL	Marijt and Falkenburg, "Specific T Cell Therapy in Leukemia," <i>Journal of Hematotherapy & Stem Cell Research</i> 10: 493-500, 2001.
	TM	Martin, A. et al., "T-Cell Receptors and Autoimmune Thyroid Disease – Signposts for T-Cell-Antigen Driven Diseases," <i>Intern. Rev. Immunol.</i> 18: 111-140, 1999.
	TN	Martin, R. et al., "Diversity in fine specificity and T cell receptor usage of the human CD4 ⁺ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106," <i>Journal of Immunology</i> 148(5): 1359-1366, March 1, 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1		APPLICATION NO. 10/729,822	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	UA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO
	UB						
OTHER ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	UC	McCarty, M.F., "Upregulation of lymphocyte apoptosis as a strategy for preventing and treating autoimmune disorders: a role for whole-food vegan diets, fish oil and dopamine agonists," <i>Med. Hypotheses</i> 57(2): 258-275, August 2001.					
	UD	McFarland, H.I. et al., "Amelioration of Autoimmune Reactions By Antigen-Induced Apoptosis of T Cells," <i>Adv. Exp. Med. Biol.</i> 383:157-166, 1995.					
	UE	McIntosh and Drachman, "Induction of Apoptosis in Activated T Cell Blasts by Suppressive Macrophages: A Possible Immunotherapeutic Approach for Treatment of Autoimmune Disease," <i>Cellular Immunology</i> 193: 24-35, 1999.					
	UF	McIntosh, R.S. et al., "Analysis of the T Cell Receptor Va Repertoire in Hashimoto's Thyroiditis: Evidence for the Restricted Accumulation of CD8 ⁺ T Cells in the Absence of CD4 ⁺ T Cell Restriction," <i>Journal of Clinical Endocrinology and Metabolism</i> 82(4): 1140-1146, 1997.					
	UG	Melms, A. et al., "Specific immune complexes augment in vitro acetylcholine receptor-specific T-cell proliferation," <i>Neurology</i> 43: 583-588, March 1993.					
	UH	Migita, K. et al., "FK506 Markedly Enhances Apoptosis of Antigen-Stimulated Peripheral T Cells By Down-Regulation of Bcl-x _L ," <i>Transplantation</i> 68(7): 1018-1023, October 15, 1999.					
	UI	Moebius, U. et al., "T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones," <i>Eur. J. Immunol.</i> 20: 889-896, 1990.					
	UJ	Murata, H. et al., "Limited TCR Repertoire of Infiltrating T Cells in the Kidneys of Sjögren's Syndrome Patients with Interstitial Nephritis," <i>The Journal of Immunology</i> 155: 4084-4089, 1995.					
	UK	Murphy, F.P. et al., "Clinical Clearing of Psoriasis by 6-Thioguanine Correlates With Cutaneous T-Cell Depletion via Apoptosis," <i>Arch. Dermatol.</i> 135: 1495-1502, December 1999.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.	
		FILING DATE December 5, 2003	GROUP ART UNIT 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
VA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
VB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

VC	Musette, P. et al., "Expansion of a recurrent V β 5.3 ⁺ T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients," <i>Proc. Natl. Acad. Sci.</i> 93: 12461-12466, October 1996.
VD	Nagahara, Y. et al., "Evidence that FTY720 induces T cell apoptosis in vivo," <i>Immunopharmacology</i> 48: 75-85, 2000.
VE	Nakashima, M. et al., "The Role of T Cells Expressing TcR V β 13 in Autoimmune Thyroiditis Induced by Transfer of Mouse Thyroglobulin-Activated Lymphocytes: Identification of Two Common CDR3 Motifs," <i>Clinical Immunology and Immunopathology</i> 80(2): 204-210, August 1996.
VF	Namekawa, T. et al., "Killer Cell Activating Receptors Function as Costimulatory Molecules on CD4 ⁺ CD28 ^{null} T Cells Clonally Expanded in Rheumatoid Arthritis," <i>The Journal of Immunology</i> 165: 1138-1145, 2000.
VG	Nijhuis, M. et al., "Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy," <i>Proc. Natl. Acad. Sci. USA</i> 95: 14441-14446, November 1998.
VH	Nikolic-Paterson, D.J. et al., "T-Cell-Specific Therapy in Autoimmune Glomerulonephritis," <i>American Journal of Kidney Diseases</i> 38(6): 1321-1328, December 2001.
VI	Nomura, Y. et al., "Twenty-five types of T-cell receptor V β family repertoire in patients with Kawasaki syndrome," <i>Eur. J. Pediatr.</i> 157: 981-986, 1998.
VJ	O'Reilly and Strasser, "Apoptosis and autoimmune disease," <i>Inflamm. Res.</i> 48: 5-21, 1999.
VK	Ogura and Handa, "Induction of apoptosis by novel synthesized acylamides of human lymphocytes," <i>Biochimica et Biophysica Acta</i> 1483: 111-118, 2000.
VL	Okamoto, R. et al., "T Cell Repertoire in Primary Biliary Cirrhosis: A Common T Cell Clone and Repertoire Change After Treatment," <i>Journal of Clinical Immunology</i> 21(4): 278-285, 2001.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.	
		FILING DATE December 5, 2003	GROUP ART UNIT 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
WA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
WB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

WC	Olive, C. et al., "Restricted junctional diversity of T cell receptor δ gene rearrangements expressed in systemic lupus erythematosus (SLE) patients," <i>Clin. Exp. Immunol.</i> 97: 430-438, 1994.
WD	Paillot, R. et al., "Activation-dependent lymphocyte apoptosis induced by methotrexate," <i>Transplant Proc.</i> 30(5): 2348-2350, August 1998.
WE	Perkins, D.L. et al., "Restriction of the TCR Repertoire Inhibits the Development of Memory T Cells and Prevents Autoimmunity in <i>lpr</i> Mice," <i>The Journal of Immunology</i> 156: 4961-4968, 1996.
WF	Pinkoski, M.J. et al., "Lymphocyte apoptosis: refining the paths to perdition," <i>Current Opinion in Hematology</i> 9: 43-49, 2002.
WG	Planey and Litwack, "Glucocorticoid-induced apoptosis in lymphocytes," <i>Biochem. Biophys. Res. Commun.</i> 279(2): 307-312, December 2000.
WH	Polanski, M. et al., "Xcellerate(: A Closed, Scalable Process for the GMP Manufacture of Stable Activated T Cells," in <i>Proceedings of the 15th Annual Scientific Meeting of the Society for Biological Therapy</i> , Seattle, October 26-29, 2000, and <i>Journal of Immunotherapy</i> , (23)5:599, September 2000.
WI	Prinz, J.C. et al., "Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris," <i>Eur. J. Immunol.</i> 29: 3360-3368, 1999.
WJ	Prinz, J.C. et al., "T cell clones from psoriasis skin lesions can promote keratinocyte proliferation <i>in vitro</i> via secreted products," <i>Eur. J. Immunol.</i> 24: 593-598, 1994.
WK	Qiao, L. et al., "T cell receptor repertoire and mitotic responses of lamina propria T lymphocytes in inflammatory bowel disease," <i>Clin. Exp. Immunol.</i> 97(2): 303-308, August 1994.
WL	Ranheim and Kipps, "Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B Cells through a CD40-dependent Signal," <i>J. Exp. Med.</i> 177: 925-935, April 1993.
WM	Ravirajan, C.T. et al., "Apoptosis in Human Autoimmune Diseases," <i>Intern. Rev. Immunol.</i> 18: 563-589, 1999.
WN	Rawlings, S.L. et al., "Spontaneous apoptosis in lymphocytes from patients with Wiskoot-Aldrich syndrome: correlation of accelerated cell death and attenuated bcl-2 expression," <i>Blood</i> 94(11): 3872-3882, December 1999.
WO	Renz, H. et al., "T cell receptor-V β repertoire in allergen-specific sensitization and increased airway responsiveness," <i>Allergy</i> 50(suppl. 25): 15-19, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.	
		FILING DATE December 5, 2003	GROUP ART UNIT 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
XA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
XB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

XC	Ria, F. et al., "Molecular Characterization of the T Cell Repertoire Using Immuno-scope Analysis and its Possible Implementation in Clinical Practice," <i>Current Molecular Medicine 1</i> : 297-304, 2001.
XD	Riddell, S.R. et al., "T-Cell Therapy of Leukemia," <i>Cancer Control 9</i> (2): 114-122, March/April 2002.
XE	Rodriguez-Palmero, M. et al., "Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo," <i>Eur. J. Immunol. 29</i> (12): 3914-3924, December 1999.
XF	Sasajima, K. et al., "Detection of T cell Apoptosis after Major Operations," <i>Eur. J. Surg. 165</i> : 1020-1023, 1999.
XG	Schmidt, D. et al., "The Repertoire of CD4 ⁺ CD28 ⁻ T Cells in Rheumatoid Arthritis," <i>Molecular Medicine 2</i> (5): 608-618, September 1996.
XH	Schmidt, J. et al., "T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy," <i>Brain 123</i> (pt. 7): 1431-1441, July 2000.
XI	Schneider, C. et al., "Experimental autoimmune myositis in the Lewis rat: lack of spontaneous T-cell apoptosis and therapeutic response to glucocorticosteroid application," <i>Journal of Neuroimmunology 107</i> : 83-87, 2000.
XJ	Shimizu, N. et al., "Large-Scale <i>ex Vivo</i> Expansion of Primary T Lymphocytes in Late-Stage AIDS Patients," <i>AIDS Research and Human Retroviruses 16</i> (6): 611-612, 2000.
XK	Smith, C.R. et al., "In vitro T cell proliferation from kidney allograft biopsies with unremarkable pathology: new strategies for an old problem," <i>Transplantation 73</i> (1): 142-145, January 2002.
XL	Snyder, M.R. et al., "Formation of the Killer Ig-Like Receptor Repertoire on CD4 ⁺ CD28 ^{null} T Cells," <i>The Journal of Immunology 168</i> : 3839-3846, 2002.
XM	Söderström, M. et al., "Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognizing multiple myelin proteins are accumulated in cerebrospinal fluid," <i>Journal of Neurology, Neurosurgery, and Psychiatry 57</i> : 544-551, 1994.
XN	Stahnke, K. et al., "Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy," <i>Blood 98</i> (10): 3066-3073, November 15, 2001.
XO	Stohl, W. et al., "Polyclonal <i>in Vitro</i> T Cell Proliferation and T Cell-Dependent B Cell Differentiation Supported By Activated Autologous B Cells," <i>Clinical Immunology and Immunopathology 72</i> (1): 44-52, July 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Ronald Berenson et al.	
		FILING DATE December 5, 2003	GROUP ART UNIT 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
YA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
YB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

YC	Strauss, G. et al., "Induction of apoptosis and modulation activation and effector function in T cells by immunosuppressive drugs," <i>Clin Exp. Immunol.</i> 128: 255-266, 2002.
YD	Takemura, S. et al., "T Cell Activation in Rheumatoid Synovium Is B Cell Dependent," <i>The Journal of Immunology</i> 167: 4710-4718, 2001.
YE	Tao, Q. et al., "Conservation of Epstein-Barr Virus Cytotoxic T-Cell Epitopes in Posttransplant Lymphomas. Implications for Immune Therapy," <i>American Journal of Pathology</i> 160(5): 1839-1845, May 2002.
YF	Tokushige, K. et al., "Abnormal T Cell Activation and Skewed T Cell Receptor V β Repertoire Usage in Japanese Patients with Idiopathic Portal Hypertension," <i>Clinical Immunology and Immunopathology</i> 75(3): 206-213, 1995.
YG	Trickett, A. et al., "Ex vivo expansion of functional T lymphocytes from HIV-infected individuals," <i>Journal of Immunological Methods</i> 262: 71-83, 2002.
YH	Vathsala, A. et al., "Inhibition of Apoptosis in Anti-CD3-Treated Peripheral Blood Lymphocytes by Immunosuppressive Drugs," <i>Transplantation Proceedings</i> 32: 1992-1994, 2000.
YI	Vavassori, M. et al., "Restricted TCR Repertoire and Long-Term Persistence of Donor-Derived Antigen-Experienced CD4 ⁺ T Cells in Allogeneic Bone Marrow Transplantation Recipients," <i>The Journal of Immunology</i> 157: 5739-5747, 1996.
YJ	Warrington, K.J. et al., "CD4 ⁺ , CD28 ⁺ T Cells in Rheumatoid Arthritis Patients Combine Features of the Innate and Adaptive Immune Systems," <i>Arthritis & Rheumatism</i> 44(1): 13-20, January 2001.
YK	Weishaupt, A. et al., "Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2," <i>Proc. Natl. Acad. Sci. USA</i> 94(4): 1338-1343, February 1997.
YL	Weishaupt, A. et al., "Glucocorticosteroids modulate antigen-induced T cell apoptosis in experimental autoimmune neuritis and cause T cell proliferation in situ," <i>Acta Neuropathol.</i> 102(1): 75-82, July 2001.
YM	White, C.A. et al., "The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis," <i>Journal of Neuroimmunology</i> 82: 47-55, 1998.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.422C1	APPLICATION NO. 10/729,822		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson et al.			
				FILING DATE December 5, 2003		GROUP ART UNIT 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	ZA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	ZB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	ZC	Wong, S. et al., "Analysis of the Peripheral T-Cell Receptor V β Repertoire in Newly Diagnosed Patients with Type I Diabetes," <i>Autoimmunity</i> 18: 77-83, 1994.					
	ZD	Wu, B. et al., "TCR Gene Usage in Experimental Autoimmune Myasthenia Gravis Pathogenesis," <i>The Journal of Immunology</i> 154: 3603-3610, 1995.					
	ZE	Wu, H. et al., "Conserved T-cell receptor β -chain CDR3 sequences in IgA nephrology biopsies," <i>Kidney International</i> 55: 109-119, 1999.					
	ZF	Wucherpfennig, K.W. et al., "T Cell Receptor V α -V β Repertoire and Cytokine Gene Expression in Active Multiple Sclerosis Lesions," <i>Journal of Experimental Medicine</i> 175: 993-1002, April 1992.					
	ZG	Xiao, B.G. et al., "Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4 ⁺ T cells," <i>J. Neuroimmunol.</i> 97(1-2): 25-36, 1999.					
	ZH	Yamada, O. et al., "Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukaemia: successful treatment with cyclosporine following <i>in vitro</i> abrogation of erythroid colony-suppressing activity," <i>British Journal of Haematology</i> 101: 335-337, 1998.					
	ZI	Yang, P. et al., "Apoptosis of infiltrating cells in experimental autoimmune uveoretinitis," <i>Chinese Medical Journal</i> 113(7): 643-646, 2000.					
	ZJ	Yu, H.G. et al., "Apoptosis of CD4 ⁺ T cells occurs in experimental autoimmune anterior uveitis (EAAU)," <i>Clin. Exp. Immunol.</i> 118: 357-363, 1999.					
	ZK	Zipp, F. et al., "Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells," <i>J. Neuroimmunol.</i> 110(1-2): 214-222, October 2000.					
	ZL	Zou, J.-P. et al., "Tumor-Bearing Mice Exhibit A Progressive Increase in Tumor Antigen-Presenting Cell Function and A Reciprocal Decrease in Tumor Antigen-Responsive CD4 ⁺ T Cell Activity," <i>The Journal of Immunology</i> 148(2): 648-655, January 15, 1992.					
	ZM						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							